Triazolam

Routes
Oral (PO)
Half-Life (t½)
PO: 2.6h
Formula
C17H12Cl2N4
Molecular Weight
343.21 g/mol
PubChem CID
5556
Aliases
Halcion

Pharmacological Mechanism

Short-acting triazolobenzodiazepine — positive allosteric modulator at GABA-A BZD site (α1-preferring). Used for short-term insomnia and procedural sedation. Extensively metabolized by CYP3A4 — sensitive to CYP3A inhibitors (azoles, ritonavir, clarithromycin) which can extend the t½ markedly. Rapid onset, short duration.

Half-Life & Elimination Curve (PO: 2.6h)

100%50%25%12.5%0%0h0×t½2.6h1×t½5.2h2×t½7.8h3×t½10.4h4×t½13h5×t½0×t½ (0h): 100% remaining (~0.983 µg/L)1×t½ (2.6h): 50% remaining (~0.492 µg/L)2×t½ (5.2h): 25% remaining (~0.246 µg/L)3×t½ (7.8h): 12.5% remaining (~0.123 µg/L)4×t½ (10.4h): 6.3% remaining (~0.0615 µg/L)5×t½ (13h): 3.1% remaining (~0.0307 µg/L)
Plasma (PO)t½ Decay (2.6h)Effect Site (ke0)
  • 0×t½0h100% (0.983 µg/L)
  • 1×t½2.6h50% (0.492 µg/L)
  • 2×t½5.2h25% (0.246 µg/L)
  • 3×t½7.8h12.5% (0.123 µg/L)
  • 4×t½10.4h6.3% (0.0615 µg/L)
  • 5×t½13h3.1% (0.0307 µg/L)
Elimination t½2.6h (PO)
Rate Constant (ke)0.267 h⁻¹
Time to Peak (Tmax)1.4h
Est. Peak (Cmax)0.983 µg/L
Clearance (CL)20.5 L/h
97% Washout (5×t½)13h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References